Merck menaikkan prakiraan penjualan seiring momentum obat-obat baru (MRK:NYSE)
· seekingalpha.com
Laba Q2 Merck melampaui estimasi berkat penjualan Keytruda dan Winrevair; pendapatan naik 5% dan panduan setahun penuh dinaikkan.
Merck (MRK) reported second-quarter results that topped Wall Street expectations, driven by continued strength in its blockbuster cancer drug Keytruda, as well ...